TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00732537
Drug: Oxygen (>90% by hood) - standard therapy
Normalized name: oxygen 90 %
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen (\>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment.
Study: NCT02094365
Drug: ALS-008176
Normalized name: ALS-008176
DrugBank: Lumicitabine (DB14808)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00865280
Drug: linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
Study: NCT00865280
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution
Study: NCT00874419
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: erlotinib 150 mg oral, once a day
Study: NCT00874419
Drug: gemcitabine/carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
Study: NCT00056797
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00947882
Drug: Degarelix 10 mg
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg degarelix, 40 mg/mL solution
Study: NCT00947882
Drug: Degarelix 20 mg
Normalized name: DEGARELIX 20 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [FIRMAGON]
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg degarelix, 40 mg/mL solution
Study: NCT00947882
Drug: Degarelix 30 mg
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg degarelix, 40 mg/mL solution
Study: NCT00860548
Drug: currently available therapy in the community
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
Study: NCT02644876
Drug: Penehyclidine inhalation
Normalized name: Penequinine, Penehyclidine
DrugBank: Penequinine, Penehyclidine (DB16287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
Study: NCT00073476
Drug: traxiprodil (CP-101,606)
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01385527
Drug: Topical Triamcinolone
Normalized name: triamcinolone Topical Cream
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical triamcinolone to all affected areas once daily
Study: NCT01906762
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
Study: NCT03445663
Drug: AMG 424
Normalized name: AMG 424
DrugBank: AMG 424 (DB17357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IV infusions of AMG 424
Study: NCT00194038
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
Study: NCT00138866
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01575626
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices.
Study: NCT01508806
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of 0.75 mg, administered as a subcutaneous injection
Study: NCT03181529
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
Study: NCT03126318
Drug: COR-001
Normalized name: Aspi-Cor
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-inflammatory therapy
Study: NCT02784067
Drug: Sucraid
Normalized name: Sucraid
DrugBank: Sacrosidase (DB06760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug
Study: NCT02211170
Drug: Lipopolysaccharide
Normalized name: Lipopolysaccharide
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipopolysaccharide (LPS) for endotoxin challenge
Study: NCT03985969
Drug: elafibranor
Normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elafibranor 120mg is a coated tablet for oral administration
Study: NCT03985969
Drug: CHRONO-INDOCID
Normalized name: Indocid
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
Study: NCT01151904
Drug: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
Study: NCT01151904
Drug: latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost administered in the affected eye(s) as prescribed by physician.
Study: NCT01311141
Drug: doripenem
Normalized name: Doripenem
DrugBank: Doripenem (DB06211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doripenem once i.v.500mg
Study: NCT00794313
Drug: Amantadine 300 mg
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine, 300 mg, capsule, three times a day, two weeks
Study: NCT00794313
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week
Study: NCT00794313
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill, capsule, three times a day, 2 weeks
Study: NCT00851227
Drug: conivaptan hydrochloride
Normalized name: Conivaptan Hydrochloride
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous
Study: NCT04660916
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
Study: NCT01286896
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses.
Study: NCT02379637
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03959397
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel monotherapy or combination therapeutic regimen
Study: NCT00386191
Drug: clopidogrel (SR25990C)
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral administration
Study: NCT02923557
Drug: Pirarubicin
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
Study: NCT00823875
Drug: Cilostazol group
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
Study: NCT00823875
Drug: Probucol group
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
Study: NCT00823875
Drug: Cilostazol + Probucol group
Normalized name: Probucol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
Study: NCT03795272
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2:1 randomization to receive rucaparib/placebo twice daily for 24 month
Study: NCT00006100
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03617328
Drug: Montanide ISA-51
Normalized name: isopropyl alcohol
DrugBank: Incomplete Freund's adjuvant (DB17475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
Study: NCT03617328
Drug: polyICLC
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: polyICLC, local adjuvant
Study: NCT03617328
Drug: CDX-1127
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-1127, anti-CD27 monoclonal antibody
Study: NCT01030926
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose
Study: NCT01030926
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose
Study: NCT01867697
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01867697
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01867697
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01867697
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01867697
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02722018
Drug: GDC-0810 Phase II Tablet
Normalized name: GDC-0810
DrugBank: GDC-0810 (DB12253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
Study: NCT02722018
Drug: GDC-0810 Phase III Prototype Tablet
Normalized name: CARDIOTOXIN III
DrugBank: GDC-0810 (DB12253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
Study: NCT00706342
Drug: Fostamatinib Disodium / R935788
DrugBank: Tamatinib (DB07159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R935788 tablets
Study: NCT01034670
Drug: fluorescent Peptide
Normalized name: EMI-137 (fluorescent peptide targeted against c-met)
DrugBank: EMI-137 (DB19174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: microdosing; Topical through the endoscope
Study: NCT01034670
Drug: fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mcg topical
Study: NCT01034670
Drug: indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg topical
Study: NCT02254954
Drug: Macitentan in combination with RT and TMZ
Normalized name: macitentan and tadalafil
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
Study: NCT02001636
Drug: Resource Instant Protein 88
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
Study: NCT02001636
Drug: Resource Maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
Study: NCT04681105
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04681105
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT04681105
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02382380
Drug: Gadoterate
Normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
Study: NCT03304938
Drug: Lavender Oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
Study: NCT01396070
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10.
Study: NCT02657603
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injected through the new Catheter (LAX)
Study: NCT02657603
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injected through the new Catheter (SAX)
Study: NCT00456027
Drug: rhGAD65 formulated in Alhydrogel® (Diamyd®)
DrugBank: rhGAD65 (DB04963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
Study: NCT03803241
Drug: CD133+ infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of cells cd133+
Study: NCT00695929
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT00695929
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT02174822
Drug: AVP-786
Normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02174822
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02174822
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02929407
Drug: FE 204205
Normalized name: Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial.
Study: NCT03418961
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01160822
Drug: Placebo to canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intra-articular injection
Study: NCT03037580
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sustained-release oral tablets for TID administration
Study: NCT00152269
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg Tablet, oral Daily for 12 months
Study: NCT00152269
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg Tablet, oral Daily for 12 months
Study: NCT00254930
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03200886
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
Study: NCT01250418
Drug: Ketamine group
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
Study: NCT00504530
Drug: Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
DrugBank: Emfilermin (DB06562)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01167244
Drug: BMS-690514
Normalized name: BMS-690514
DrugBank: BMS-690514 (DB11665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
Study: NCT01324401
Drug: Peanut flour OIT
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
Study: NCT04582981
Drug: Fruquintinib and raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
Study: NCT01122121
Drug: Leuprorelin SR
Normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin SR injection
Study: NCT01122121
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide tablets
Study: NCT01708902
Drug: linagliptin2.5mg/metformin1000mg
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: linagliptin2.5mg/metformin1000mg BID
Study: NCT01708902
Drug: linagliptin 5mg
Normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin 5mg once daily